Short-term efficacy and safety analysis of immunotherapy for advanced non-small cell lung cancer
Objective:To study the short-term efficacy and safety of immunotherapy for advanced non-small cell lung cancer(NSCLC).Methods:62 patients with NSCLC from January 2022 to January 2023 in Jiangyin People's Hospital were selected.Randomly divided into two groups,31 cases each.The control group received routine chemotherapy,while the study group received routine chemotherapy combined with immunotherapy.The levels of tumor markers,clinical efficacy and adverse reactions were compared between the two groups.Results:Before treat-ment,there was no significant difference in the levels of CA199、CEA and SCC between two groups(P＞0.05).Af-ter treatment,the levels of CA199、CEA and SCC in the study group were lower than those in the control group,and the difference was statistically significant(P＜0.05).Compared with the control group,the total effective rate in the study group was higher,and the difference was statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion:NSCLC immunother-apy has better short-term efficacy and good safety,which can effectively improve the disease control rate and con-trol tumor progression.
国家科技期刊平台
NSTL
万方数据
